BridgeBio Pharma, Inc. (BBIO) vs Jazz Pharmaceuticals PLC (JAZZ)
BridgeBio Pharma, Inc. and Jazz Pharmaceuticals PLC are both Biotechnology companies. Jazz Pharmaceuticals PLC is the larger, with a market value of $15.3B against $13.1B — 1.2× the size. BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Jazz Pharmaceuticals PLC trades at 15.6×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 202.4% against 12.6%. Jazz Pharmaceuticals PLC has the higher net margin (20.5% vs −97.0%) and the higher return on invested capital (8.06% vs 0.00%). Across the 17 metrics below, Jazz Pharmaceuticals PLC leads on 10 and BridgeBio Pharma, Inc. on 7.
Valuation
Profitability
| Metric | BBIO | JAZZ | Biotechnology median |
|---|---|---|---|
| Gross margin | 94.44% | 88.42% | 65.16% |
| Operating margin | (69.81%) | 19.49% | 0.00% |
| Net margin | (97.03%) | 20.45% | 0.00% |
| Free cash flow margin | (61.06%) | 30.79% | 0.00% |
| Return on equity | 32.31% | 22.11% | (57.72%) |
| Return on assets | (60.23%) | 8.54% | (49.22%) |
| Return on invested capital | 0.00% | 8.06% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack